IMC-nyeso (Immunocore)

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameIMC-nyeso (Immunocore)

Drug Alias NameNY-ESO-1-ImmTACNY-ESO-ImmTACIMCnyesobispecific NY-ESO-1- and LAGE-1A-specific TCR/anti-CD3HLA- A*0201-restricted NY-ESO-1- and LAGE-1A-specific soluble TCR/anti-CD3 bispecific molecule +[9]

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers

Mechanisms of ActionImmunologic cytotoxicityAnti-NY-ESO-1CD3 T-cell engagers

TargetsCancer/testis antigen 1T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesUnited Kingdom

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesImmunocore Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunocore Ltd

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A